Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-05-03
2005-05-03
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007910, C435S007920, C436S514000, C436S547000, C436S015000, C530S387500, C530S387100, C530S388200
Reexamination Certificate
active
06887673
ABSTRACT:
A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5928893 (1999-07-01), Kang et al.
patent: 6210669 (2001-04-01), Aruffo et al.
patent: 6303121 (2001-10-01), Kwon
patent: 6355779 (2002-03-01), Goodwin et al.
patent: 6458934 (2002-10-01), Hong et al.
Kim, Y. et al., Eur. J. Immunol., “Human 4-1BB Regulates CD28 Co-Stimulation to Promote Th1 Cell Responses”, vol. 28, pp. 881-890 (1998).
Ashkenazi, A., Nature, “Targeting Death and Decoy Receptors Of The Tumour-Necrosis Factor Superfamily”, vol. 2, pp. 420-430 (2002).
Pollok, K. et al., Eur. J. Immunol., 4-1BB T-Cell Antigen Binds To Mature B Cells and Macrophages, and Costimulates Anti-μ-Primed Splenic B Cells, vol. 24, pp. 367-374 (1994).
Melero, I. et al., Cellular Immunology, “NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies”, vol. 190, pp. 167-172 (1998).
Kwon, B. et al., Mol. Cells, “4-1BB: Still in the Midst of Darkness”, vol. 10, No. 2, pp. 119-126 (2000).
Rosenberg, S., Nature, “Progress in Human Tumour Immunology and Immunotherapy”, vol. 411, pp. 380-384 (2001).
Halapi, E., Medical Oncology, Oligoclonal T Cells in Human Cancer, vol. 15, pp. 203-211 (1998).
Resser, J. et al., Current Opinion in Oncology, “Immunotherapy of Head and Neck Cancer”, vol. 10, pp. 226-232 (1998).
Elder, D., Acta Oncologica, “Tumor Progression, Early Diagnosis and Prognosis of Melanoma”, vol. 38, pp. 535-547 (1999).
Zhang, L. et al., The New England Journal of Medicine, “Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer”, vol. 348, pp. 203-213 (2003).
Rosenberg, S., The Cancer Journal From Scientific American, “Interleukin-2 and the Development of Immunotherapy for the Treatment of Patients With Cancer”, vol. 6, pp. S2-S7 (2000).
Bassi, P., Surgical Oncology, “BCG (Bacillus of Calmette Guerin) Therapy of High-Risk Superficial Bladder Cancer”, vol. 11, pp. 77-83 (2002).
Fishman, M. et al., Expert Opin. Investig. Drugs, “Novel Therapies For Renal Cell Carcinoma- An Update”, vol. 12, No. 4, pp. 593-609 (2003).
Lenschow, D. et al., Annu. Rev. Immunol., “CD28/B7 System of T Cell Costimulation”, vol. 14, pp. 233-258 (1996).
Chambers, C. et al., Current Opinion in Immunology, “Co-Stimulation in T-Cell Responses”, vol. 19, pp. 396-404 (1997).
Abbas, A. et al., Cellular and Molecular Immunology 3rd ed., “T Lymphocyte Antigen Recognition and Activation”, pp. 139-170 (1997).
Hurtado, J. et al., Journal of Immunology, “Potential Role of 4-1BB in T Cell Activation”, vol. 155, pp. 3360-3367 (1995).
Futagawa, T. et al., International Immunology, “Expression and Function of 4-1BB and 4-1BB Ligand on Murine Dendritic Cells”, vol. 14, No. 3, pp. 275-286 (2002).
Wilcox, R. et al., Journal of Immunology, “Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells”, vol. 168, pp. 4262-4267 (2002).
Lindstedt, M. et al., Scandinavian Journal of Immunology, “Expression of CD137 (4-1BB) on Human Follicular Dendritic Cells”, vol. 57, pp. 305-310 (2003).
Pollock, K. et al., The Journal of Immunology, “Inducible T Cell Antigen 4-1BB”, vol. 150, No. 3, pp. 771-781 (1993).
Vinay, D. et al., Seminars in Immunology, “Role of 4-1BB in Immune Responses”, vol. 10, pp. 481-489 (1998).
Hurtado, J. et al., Journal of Immunology, “Signals Through 4-1BB Are Costimulatory to Previously Activated Splenic T Cells and Inhibit Activation-Induced Cell Death”, vol. 158, pp. 2600-2609 (1997).
Takahashi, C. et al., Journal of Immunology, “Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal”, vol. 162, pp. 5037-5040 (1999).
Alderson, M. et al., Eur. J. Immunol., “Molecular and Biological Characterization of Human 4-1BB and It's Ligand”, vol. 24, pp. 2219-2227 (1994).
DeBenedette, M. et al., Journal of Immunology, “Costimulation of CD28 T Lymphocytes by 4-1BB Ligand”, vol. 158, pp. 551-559 (1997).
Salih, H. et al., Journal of Immunology, “Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells”, vol. 165, pp. 2903-2910 (2000).
Melero, I. et al., Nature Medicine, “Monoclonal Antibodies Against the 4-1BB T-Cell Activation Molecule Eradicate Established Tumors”, vol. 3, No. 6, pp. 682-685 (1997).
Wilcox, R. et al., The Journal of Clinical Investigation, “Provision of Antigen and CD137 Signalling Breaks Immunological Ignorance, Promoting Regression of Poorly Immunogenic Tumors”, vol. 109, No. 5, pp. 651-659 (2002).
Wilcox, R. et al., Cancer Research, “Impaired Infiltration of Tumor Specific Cytolytic T Cells in the Absence of Interferon-γ Despite Their Normal Maturation in Lymphoid Organs During CD137 Monoclonal Antibody Therapy”, vol. 62, ogs. 4413-4418 (2002).
Miller, R. et al., The Journal of Immunology, “4-1BB Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Aviation of CD8 T Cells in a CD40- Dependent Manner”, vol. 19, pp. 1792-1800 (2002).
Wen, T. et al., Journal of Immunology, 4-1BB Ligand Mediated Costimulation of Human T Cells Induces CD4 and CD8 T Cell Expansion, Cytokine Production, and the Development of Cytolytic Effector Function:, vol. 168, pp. 4897-4906 (2002).
Hong, H. et al., Journal of Immunotherapy, “A Humanized Anti-4-1-BB Monoclonal Antibody Suppresses Antigen-Induced Humoral Immune Response in Nonhuman Primates”, vol. 23, No. 6, pp. 613-621 (2000).
Jones, P. et al., Nature, “Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse”, vol. 321, pp. 522-525 (1986).
Foote, J. et al., J. Mol. Biol., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”, vol. 224, pp. 487-499 (1992).
Kearney, J. et al., Journal of Immunology, “A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits the Construction of Antibody-Secreting Hybrid Cell Lines” vol. 123, No. 4, pp. 1548-1550 (1979).
Angal, S. et al., Molecular Immunology, “A Single Amino Acid Substitution Abolishes The Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody”, vol. 30, No. 1, pp. 105-108 (1993).
Saiki, R. et al., Science, “Primer-Directed Enzymatic Amplifications of DNA With A Thermostable DNA Polymerase”, vol. 239, pp. 487-491 (1987).
Loh, E. et al., Science, “Polymerase Chain Reaction With Single-Sided Specificity: Analysis of T Cell Receptor δ Chain”, vol. 243, pp. 217-220 (1989).
Chothia, C. et al., J. Mol. Biol., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, vol. 196, pp. 901-917 (1987).
Lesk, A. et al., Antibody Engineering, A Practical Guide, “Antibody Structure and Structural Predictions Useful in Guiding Antibody Engineering”, pp. 1-38 (1992).
Lane, R., Journal of Immunological Methods, “A Short-Duration Polyethylene Glycol Fusion Technique for Increasing Production of Monoclonal Antibody-Secreting Hybridomas” vol. 81, pp. 223-228 (1985).
Abraham Ralph
Ganguly Subinay
Hollenbaugh Diane L.
Kunkel Maria Jure
Mittler Robert S.
Bristol--Myers Squibb Company
Cheu Jacob
Golian Paul D.
Le Long V.
LandOfFree
Humanized antibodies against human 4-1BB does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies against human 4-1BB, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies against human 4-1BB will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3444327